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Abstract
The effects of As4O6 as adjuvant on photodynamic therapy (PDT) were studied. As4O6 is considered to have anticancer
activity via several biological actions, such as free radical production and inhibition of VEGF expression. PDT or As4O6
significantly inhibited TC-1 cell proliferation in a dose-dependent manner (P,0.05) by MTT assay. The anti-proliferative
effect of the combination treatment was significantly higher than in TC-1 cells treated with either photodynamic therapy or
As4O6 alone (62.4 and 52.5% decrease compared to vehicle-only treated TC-1 cells, respectively, P,0.05). In addition, cell
proliferation in combination of photodynamic therapy and As4O6 treatment significantly decreased by 77.4% (P,0.05). Cell
survival pathway (Naip1, Tert and Aip1) and p53-dependent pathway (Bax, p21
Cip1, Fas, Gadd45, IGFBP-3 and Mdm-2) were
markedly increased by combination treatment of photodynamic therapy and As4O6. In addition, the immune response in
the NEAT pathway (Ly-12, CD178 and IL-2) was also modulated after combination treatment, suggesting improved
antitumor effects by controlling unwanted growth-stimulatory pathways. The combination effect apparently reflected
concordance with in vitro data, in restricting tumor growth in vivo and in relation to some common signaling pathways to
those observed in vitro. These findings suggest the benefit of combinatory treatment with photodynamic therapy and
As4O6 for inhibition of cervical cancer cell growth.
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Introduction
Photodynamic therapy (PDT) involves the combination of non-
toxic dyes known as photosensitizers (PSs) and visible light of the
correct wavelength to be absorbed by the PSs. In the presence of
oxygen, this leads to generation of reactive oxygen species (ROS)
that can damage cellular constituents, leading to cell death [1,2].
The discovery of programmed cell death, or apoptosis, has
revolutionized the field of cytotoxic therapy in general, and PDT
in particular [3–5]. However, a complete eradication of tumor
cells by PDT alone has not been guaranteed [6]. Further study of
controlling unwanted growth-stimulatory pathways after PDT is
desirable to minimize the risk of harmful adverse effects.
Arsenical compounds have been demonstrated to possess life-
preserving qualities in cancer treatment [7–10]. Promising results
were reported, showing that diarsenic oxide (As2O3) treatment
could offer an alternative to chemotherapy for acute promyelo-
cytic leukemia (APL). Cytopathological studies also showed
induction of apoptosis in APL cells. Recent reports suggested that
arsenical compounds inhibit the proliferation of human umbilical
vein endothelial cells (HUVEC) via G1 and G2/M phase arrest of
the cell cycle [8]. In addition, the inhibitory effects on bFGF- or
VEGF-stimulated cell proliferation suggest the antiangiogenic
potential of arsenical compounds [11]. Furthermore, tetra-arsenic
oxide (As4O6) was reported to have antiangiogenic effects on the
NGF-induced formation of new vessels in the rat cornea,
compared to control group and As2O3 treated group [9]. It has
been therefore suggested that As4O6 might be a new arsenic
compound, as it induced apoptosis in cancer cells at much lower
concentration than As2O3 [10]. Arsenic compounds can increase
reactive oxygen species (ROS) in cells and thereby increase
apoptosis inducing factor (AIF) secretion through activation of
PARP-1, and finally induce cell apoptosis. The release of
cytochrome c and apoptosis inducing factor (AIF) is finely tuned
by Bcl-2 family proteins in either of the following two ways:
according to one possible mechanism, Bax present in the
cytoplasm is translocated to the mitochondrial membrane, where
it undergoes conformational changes assisted by Bid. The binding
of Bax to the outer membrane (OM) causes its in situ multi-
merization, whereby PTP is gated and cytochrome c is released.
Bcl-2 and Bcl-xL inhibit conformational changes in Bax and
therefore inhibit release of cytochrome c and apoptosis. High level
of ROS production is the main cause of apoptosis by arsenic
compound. As free radical, ROS can react with most biological
macromolecules, and therefore not only can induce oxidative
damage on DNA, but also change structure and function of
protein [12–14].
On the other hand, ROS can modulate genetic expression by
acting as a second messenger. Several studies have suggested that
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and could help induce the initiation of apoptosis after an increase
in cell proliferation [15,16]. Arsenic compound could also
reportedly regulate the immune response to involve anti-cancer
function, through decrease of VEGF expression [12–14].
In this study, we firstly showed the enhanced anti-tumor effect
of PDT using Radachlorin with As4O6 in mice bearing tumors
caused by human papillomavirus (HPV) 16 E6/E7 oncogene
expressed TC-1 tumor cells. The present study showed that the
combination therapy of PDT plus As4O6 was much more effective
on the suppression of tumor growth, compared with PDT or
As4O6 alone.
Results
In vitro cell growth inhibitory effect of As4O6 plus
Radachlorin/PDT on TC-1 cells
To see the growth inhibition effect of PDT on TC-1 cell, the
light of 6.25J/cm
2 was exposed at 12 hr after Radachlorin
treatment on the cells, and then the cell growth was measured for
a predetermined time. Viability of cells treated with various doses
of Radachlorin followed by light irradiation was reduced in a dose
dependent manner compared to control, respectively (Figure 1A).
To see the growth inhibition effect of As4O6 on TC-1 cell, the cell
growth was measured for a predetermined time after As4O6
treatment. Viability of cells treated with various doses of As4O6
was reduced in a dose dependent manner compared to control,
respectively (Figure 1B). Using these data, the viability of cells was
determined after treating the cultured TC-1 cells with 3 uM of
As4O6 and different doses of Radachlorin/PDT per day. The
combination treatment showed synergistic effect, decreasing
viability in a dose dependent manner as compared to control, as
shown in Figure 1C. Cell viability was found to be 62.4% for PDT
alone and 52.5% after As4O6 alone treatment at a low dose. In
contrast, after PDT plus As4O6 treatment, the percentage of cell
growth was found less than 23%. We also observed the combined
effect vs. single doses over time to elucidate whether the
combinatory approach can result in longer-lived restriction of cell
proliferation compared to individual therapies (Figure 2). Cell
viability was found to be less than 10% for 0.2 ug/ml of
Radachlorin/PDT plus As4O6 treatment for three days, as
compared to individual treatment. For the evaluation of synergism
between Radachlorin/PDT and As4O6 treatment, we used
a combination index that calculated by Chou and Talalay’s
method (Table 1). Among the several combinations of treatment,
0.2 ug/ml Radachlorin/PDT plus 3 uM of As4O6 on day 3 and 4
led to the highest cell death rate and it showed synergism. A few
more cell lines such as HaCaT, HeLa, and SiHa cells were
included for evaluating the inhibition of cell growth (Supplement
Figure S1). While the results of HaCaT and SiHa were consistent
with earlier estimates of MTT assay, HeLa showed Radachlorine/
PDT-resistant trend compared to the other cells. The cell viability
of the two cell line was found to be less than 25% for 0.15 ug/ml
of Radachlorin/PDT plus As4O6 treatment for four days, as
compared to individual treatment. We characterized cell death by
staining the TC-1 cells treated with 0.15 ug/ml Radachlorin/
PDT or/and 3 uM of As4O6 for 1 day. As expected, the effect of
the combination treatment was larger than each single treatment.
In the absence of Radachlorin/PDT or As4O6, the cells achieved
a completely confluent, dense monolayer after 48 h of culture
(Figure 1D). The cells remained attached to the tissue culture
substrate and they adopted an elongated morphology. In contrast,
the majority of the cells treated with Radachlorin/PDT plus
As4O6 was detached from the plate and was rounded; character-
istic of cells undergoing death by apoptosis. The cells treated with
Radachlorin/PDT or As4O6, however, adopted morphologies that
were intermediate in nature. We counted different apoptotic cell
populations induced by 0.15 ug/ml Radachlorin/PDT or/and
3u Mo fA s 4O6 for 1 day. As shown in Supplement Figure S2, the
cell death significantly increased after Radachlorin/PDT plus
As4O6 treatment. Early apoptotic population was 9.9% at
Radachlorin/PDT plus As4O6 treatment. In contrast, early
apoptotic cell populations were 4.3% and 4.1% at Radachlorin/
PDT and As4O6 treatment, respectively. This shows that the
combination treatment induced more early apoptotic cells
compared to individual therapies.
Gene expression profile of TC-1 cells treated with As4O6
plus Radachlorin/PDT
We used RT
2 Profiler PCR Array System to understand the
cellular process changes through which TC-1 cells could be
influenced by the combination treatment with As4O6 plus
Radachlorin/PDT. We found 63 genes which were at least two
fold up- or downregulated (each gene is detailed in Table 2) and
used hierarchical clustering to show differentially expressed genes
(Figure 3A). To detect the differences in the functional profiles, we
placed differentially expressed genes in the context of present
interactome knowledge, using the Ingenuity Pathways Analysis
tools (P for all ,0.05), showing that the enhanced cell growth
inhibition and antitumor effects were significantly related with
gene expression levels of genes related with cell death, i.e. p53 and
NFAT pathway (Figure 3B). Each gene in the pathway was tested
by quantitative PCR (Figure 4) and the results of the PCR array
and qRT-PCR were similar. These included genes coding for
Tert, Aip1, Bax, p21, Fas, Gadd45, IGFBP-3, Mdm-2, Ly-12, and
IL-2, as compared to slightly expressed genes such as Naip1 and
CD178. Significantly up-regulated molecular functions for the
combination treatment group was p53 pathway. The down-
regulated molecular function was NEAT pathway. MAPK,
cytokine-cytokine receptor interaction, focal adhesion, cell adhe-
sion pathways were also studied in the gene sets, but not strictly
correlated with the enhanced cell growth inhibition (P for all
.0.05) (Figure 3C–F).
As4O6 plus Radachlorin/PDT suppresses tumor growth in
TC-1 animal model
To determine the synergistic antitumor effects of As4O6 plus
Radachlorin/PDT in vivo, C57BL/6 mice were challenged s.c.
with TC-1 cells and then treated with As4O6 or/and Rada-
chlorin/PDT. Treatment was initiated on day 0 when tumors
were ,230 mm
3 in size. As shown in Figure 5A, As4O6 or
Radachlorin/PDT treated animal groups showed significant
suppression of tumor growth, compared to the untreated control
group. However, animals treated with combination of As4O6 plus
Radachlorin/PDT showed the most significant tumor suppression,
compared to the other groups. This suggested that As4O6 may
play an important role in inhibiting the growth by Radachlorin/
PDT.
Effect of arsenic treatment on regional blood perfusion in
tumor tissue
Hoechst 33342 was used to visualize perfused vessels as
described in material and methods. In control tissue, vascular
endothelial cells were clearly stained by Hoechst 33342 at both
their outer edge and central region (Figure 5B). Treated tissue was
centrally destained and the periphery florescence signal was almost
undetectable. This phenomenon continued to the 24 h point.
Synergistic Combination of Photodynamic Therapy
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at 48 h post-treatment, while central staining still remained absent.
In order to observe changes of vessel function in whole tumor,
tumor section were scanned field by field. The sequential perfusion
area changes after As4O6 treatment are shown in Figure 5C. At
each time point, the percentage of every section to tumor field was
comparable to control tissue at each time point. The perfusion
area was reduced immediately after As4O6 treatment. At 6 and
12 hr, the perfusion area was the minimum, at 24 h the perfusion
area was 14.4% compared with tissue from PBS treated control
tissue. Tumor microvessel density dimensions were measured after
the administration of As4O6 to mice bearing TC-1 tumor
xenografts. As shown in Figure 5D, there was a significant
difference in tumor vessel density as detected by CD31 staining
between the As4O6-treated group and the time-matched PBS
treated control group after 24 hr of As4O6 treatment. Mice treated
with As4O6 had a reduction in tumor vessel dimensions compared
with the control animals, with CD31 stained microvessels still
being apparent at the outer edge of the tumor.
In vivo gene expression levels of tumor tissues treated
with As4O6 plus Radachlorin/PDT
TC-1 cells were treated with As4O6 and Radachlorin/PDT for
1 day, as indicated in the ‘‘Materials and Methods’’ section. The
expression of genes mRNA in tumor tissues was examined by
qRT-PCR (Figure 6A). The results are presented as transcript
levels relative to the level in untreated control cells by using the
CT method, and b-actin mRNA levels were used as the
normalization control. Using CD5 antigen in the combination
therapy group, Ly-12 and IL-2 gene expression increased 26 and
17 fold, respectively, compared to the control group, showing that
p53 was involved in regulating the NFAT pathway of p21,
Gadd45, IGFBP-3, Mdm-2 and other genes. Gene expression was
found increased in three consecutive experiments. To determine
the roles of p53 signaling pathways in the synergistic antitumor
effects of As4O6 plus Radachlorin/PDT in vivo, we further
investigated the p53, p21, and Gadd45 protein levels in vivo
(Figure 6B). As4O6 or Radachlorin/PDT treated animal groups
showed no significant expression changes, compared to the
Figure 1. Cell growth inhibition effects of photodynamic therapy and As4O6. (A) TC-1 cells (3610
3) were cultured in 12-well plates in
triplicate overnight and treated with different concentrations of Radachlorin and PDT (6.25 J/cm
2) as described in Materials and Methods. After PDT,
the cells were cultured for a predetermined time. (B) Inhibition effects of cell growth of As4O6 on TC-1 cells. TC-1 cells were cultured and treated as
described in Materials and Methods. After As4O6 treatment, the cells were cultured for a predetermined time. Cell viability was determined based on
the MTT assay. (C) In vitro cell growth inhibitory effects of As4O6 plus Radachlorin/PDT on TC-1 cells. TC-1 cells were cultured with 3 uM of As4O6 and
different doses of Radachlorin/PDT for 1 day, as described above. Cell viability was determined based on the MTT assay. Each bar represents a mean
[6 SD (vertical line)] of three replicates per dose (n=3). * and #: significantly different (P,0.05) from the control and the PDT by the student’s t-test.
(D) Morphological changes of TC-1 cells. TC-1 cells were treated with 0.15 ug/ml Radachlorin/PDT or/and 3 uM of As4O6 for 1 day. Cells were then
viewed under microscope. Pictures were taken with phase contrast microscopy at X300. (a) non-treated; (b) 0.15 ug/ml Radachlorin/PDT alone; (c)
3u MA s 4O6 alone; (d) 3 uM As4O6 plus 0.15 ug/ml Radachlorin/PDT.
doi:10.1371/journal.pone.0038583.g001
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protein were significantly increased in the combination treatment
with As4O6 plus Radachlorin/PDT.
Discussion
In this study, we comparatively analyzed results of single
treatment of As4O6 or photodynamic therapy groups with those
obtained by the co-treatment using E6/E7 expressing TC-1 cell
line and C57BL/6 mouse model transplanted with this cell. We
finally report the enhanced cell growth inhibition and antitumor
effects and changes in gene expression levels of genes related with
cell death, i.e. p53 and NFAT pathway, induced by this As4O6
and PDT co-treatment method.
These effects were produced by the photodynamic therapy
depending on the concentration of the photosensitizer Rada-
chlorin, and by the As4O6 treatment in a concentration dependent
manner. In the PDT-untreated cells, the cell growth was
consistently maintained until the end of the observation period.
PDT-treated cells were regressed only for 1 day post-PDT, but the
cell growth was re-increased after 2 days post-PDT. The lower the
As4O6 level was, the slower the cell growth inhibiting effect was
shown. Under 3 uM of As4O6, cell growth inhibition seemed to
begin on the 1st day of treatment and was consistently maintained
under 60,80% level of cell growth during the first 4 days of
treatment. In contrast, concentrations of As4O6 higher than 3 uM
seemed to be cytotoxic. In the co-treatment group of As4O6 and
PDT, more significant effects on cell growth inhibition and more
morphological changes were found, compared to each single-
treatment group. It has been known that antitumor agents
generate reactive oxygen and reactive nitrogen species to induce
apoptosis and necrosis of the cell [17–19]. As one of the antitumor
agents, the antitumor mechanism of arsenic compound to generate
reactive oxygen and nitrogen species in the colorectal cancer cell
line has also been reported [20]. The supply of sufficient oxygen
and the generation of reactive oxygen species (ROS) are known to
be significant factors determining the effect of photodynamic
therapy [4,21]. Therefore, induction of ROS mediated by
antitumor agents might have contributed to enhancing the
efficiency of PDT.
Next, we comparatively analyzed the change of intracellular
signal pathway of each single-/co-treatment group, using the
RT
2Profiler
TM PCR array method, and those results were
confirmed by the real-time PCR examination using 13 different
primers. Using the real-time PCR method, we analyzed the
change in expression levels of 84 genes involved in 15 signaling
pathways. We found significant changes in the expression levels of
genes known to be involved in cell survival pathway (e.g., Naip1,
Tert, Aip1, etc.), p53 pathway (e.g., Bax, p21, Fas, Gadd45,
IGFBP-3, Mdm-2, etc.), and NFAT (nuclear factor of activate T-
cell) pathway (e.g., Ly-12, CD178, IL-2, etc.) involved in
modulation of the immune response. Especially, expression levels
of Naip1, which is known as the apoptosis inhibitory gene, and
Tert, the telomerase reverse transcriptase, were decreased in every
cell survival pathway, whereas the expression level of the apoptosis
inducing gene Aip1 was enhanced. Moreover, the PCR array
results showed decreased levels of Tert gene expression of 2.7,
17.1, and 34.6 fold in As4O6 alone, PDT alone, and co-treatment
groups, respectively, each compared to the control group. Tert
gene is known to be related with activation of telomerase, and in
case of cervical cancer, the c-myc gene seems to induce telomerase
activation by Tert expression [22]. Therefore, we suggest that
down-regulation of the Tert gene induced by this co-treatment of
As4O6 and PDT might have been involved in cell death. The
inhibition of Tert gene was also confirmed by the real-time PCR
examination performed after RT
2 Profiler
TM PCR array analysis,
and this reduction of Tert gene expression level was consistently
shown in the co-treatment group, both in vitro and in vivo.
Figure 2. In vitro cell growth inhibitory effects of As4O6 plus
Radachlorin/PDT on TC-1 cells. TC-1 cells were cultured with 3 uM
of As4O6 and (A) 0.15 ug/ml and (B) 0.2 ug/ml of Radachlorin/PDT,
respectively. Cell viability was determined based on the MTT assay. Each
bar represents a mean [6 SD (vertical line)] of three replicates (n=3). *
and #: significantly different (P,0.05) from the control and the PDT by
the student’s t-test.
doi:10.1371/journal.pone.0038583.g002
Table 1. Combination index (CI) values for TC-1 cells treated with Radachlorin/PDT and As4O6.
Day 1 Day 2 Day 3 Day 4
As4O6 PDT f*(%) CI** f(%) CI f(%) CI f(%) CI
3uM 0.2ug/ml 17.3 1.61 9.7 1.16 8.2 0.98 8.7 0.67
3uM 0.15ug/ml 22.6 1.52 12.7 1.13 15.7 1.02 26.4 1.19
The combination index (CI) values were calculated using the Chou and Talalay mathematical model for drug interaction on Calcusyn software. A CI was equal to 1
denotes additivity; antagonism if the CI.1; CI values between 1 and 0.7 indicate slight synergism; 0.7 to 0.3, synergism; ,0.3, strong synergism. *Viability.
doi:10.1371/journal.pone.0038583.t001
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Gadd45, IGFBP-3, and Mdm-2 genes, known to be involved in
the p53 pathway, and the co-treatment group showed more
significant increase compared to each single-treatment group.
However, any significant change of Bax gene expression (known to
be activated by p53) was not observed. Moreover, from the
absence of significant changes of p53 level, those changes of p21,
Fas, Gadd45, IGFBP-3, and Mdm-2 gene expression levels seem
to be mediated by p53-independent pathways.
In addition, considering the expression levels of genes like Ly-
12, CD178, and IL-2, known to be involved in the NFAT
pathway, Ly-12 expression increased, whereas CD178 and IL-2
expressions rather decreased in the co-treatment group, compared
to each single-treatment group. As the intracellular pathway of
NFAT has been known to be associated with increased immune
responses, we expected that it might be up-regulated by PDT;
however, the gene expression levels in this pathway, including IL-
2, decreased after PDT treatment and further decline was found in
the co-treatment group. However, when we tried to confirm the
Figure 3. Hierarchical cluster analysis. (A) All the data were median centred and clustered using a hierarchical clustering. A cluster image
representing 63 of the genes is shown in matrix format, where rows represent individual genes and columns represent each assay. Each cell in the
matrix represents the expression level of a gene in an individual assay. Red and green cells reflect high and low expression levels, respectively. (B) Ten
genes (p53 and NEAT pathways) showing statistically significant differences in three groups are shown as a cluster image. (C) MAPK pathway as
a cluster image. (D) Cytokine-cytokine receptor interaction pathway. (E) Focal adhesion pathway. (F) Cell adhesion pathway.
doi:10.1371/journal.pone.0038583.g003
Synergistic Combination of Photodynamic Therapy
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38583results of RT
2Profiler
TM PCR array using the real-time PCR
method, we found opposite results compared to those of
RT
2Profiler
TM PCR array, i.e. IL-2 expression decreased in the
PDT alone treatment group and increased in the co-treatment
group, both showing similar results under in vitro and in vivo
conditions. It was reported that PDT might stimulate tumor
growth-promoting immune signals and could be improved by
controlling unwanted growth-stimulatory pathways [23,24].
Therefore, our results for IL-2 seem to show that PDT decreased
the expression of this gene, whereas it was increased by the arsenic
compound treatment, indicating that the combination therapy
combine two advantages by inducing immune mediators and
antitumor effects. In addition, this concurrent treatment increased
the in vitro and in vivo expression levels of the CD5 antigen gene and
Ly-12 up to 23 and 26 fold, respectively. However, expression
levels of Ly-12 or IL-2 did not show significant changes in the
PDT alone treatment group; therefore, the increased gene
expression seemed to be induced by the arsenic compound. So
far, however, no other studies have reported the relationship
between the combined PDT-As4O6 treatment and the NFAT
pathway, and more intensive studies should be carried out.
Similarly, our TC-1 cell line-transplanted mouse model showed
significantly enhanced antitumor effect in the PDT and As4O6 co-
treatment group, compared to each single-treatment group. To
identify the mechanism of this effect, we performed real-time PCR
experiment using 10 different primers and finally observed
significant changes in the expression levels of genes known to be
involved in the cell survival pathway, p53 pathway, and NFAT
pathway, similar with those obtained from in vitro experiments.
Our western blot data demonstrates that co-treatment increased
expression of p53, p21, Gadd45 at 7 day compared to single-agent
treatment and control. Activation of p53 protein plays a crucial
role in the control of tumor cell response to chemotherapeutic
agents and DNA-damaging agents. p21 and GaDD45, down-
stream effectors of p53, were activated in combination treatment
producing apoptosis in TC-1 tumor cells. These results suggest
that apoptosis may be mediated through the p53 signaling
pathway via up-regulation of proapoptotic proteins.
During PDT, intracellular depletion of oxygen and collapsed
blood vessels might induce intracellular hypoxia and this could up-
regulate the level of VEGF expression to catalyze angiogenesis
[25]. Many studies on PDT have been trying to increase the
efficiency of this method by supporting the generation of
intracellular ROS, or by performing this method in combination
with several inhibitors of angiogenesis, such as COX-2, MMP, or
VEGF [9,26–31]. Arsenic compounds are currently used as
therapeutic agents for acute leukemia and various solid tumors,
and they also have been reported to generate ROS and inhibit the
VEGF expression [17,19]. In this study, the vascular disruption
effect of As4O6 was determined by Hoechst33342 perfusion and
CD31 immunohistochemistry staining. Blood perfusion area
decreased rapidly after As4O6 treatment. From the 3 h time
Figure 4. In vitro gene expression profiles using RT
2Profiler
TM PCR array of TC-1 cells treated with 0.15 ug/ml Radachlorin/PDT or/
and 3 uM of As4O6 for 1 day. The results are presented as transcript levels relative to the level in untreated control cells by using the CT method,
with average mRNA level of five internal control genes, including b-actin, used as the normalization control. (A) Cell survival pathway. (B) NEAT
pathway. (C) p53 pathway.
doi:10.1371/journal.pone.0038583.g004
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perfusion activity and, finally, almost no signal could be detected
in the whole tumor area, even the outer edge. Interestingly, this
reduction of the perfusion area was recovered from the 24 h time
point, and the florescence appeared from the outer edge clearly at
48 and 72 h. Even though the blood perfusion appeared to be
recovered from the outer edge 72 h after treatment, no signal was
detected from inside of the tumors. These data showed that much
more intensive immunoreactive microvessels were observed in
tumor tissues from mice treated with PBS, but little CD31 staining
was present in the central region of tumor tissues from mice
treated with As4O6. The results echo those of studies involving
As2O3 and Conbretastatin A-4 [32,33]. As2O3 decreased blood
perfusion relative to controls up to 6 h after As2O3 treatment with
some recovery at 24 h [32], and also CA-4-P, 24 h after treatment
on P22 tumors vascular functions displayed partial recover [33].
Therefore, in this study, we used one of the arsenic compounds,
i.e. As4O6, in combination with the PDT method to investigate the
increasing antitumor effect and also its intracellular signaling
pathways. These data showed that the effect of the combinatory
therapy on VEGF and associated pathways were strengthened
with the assessments of tumor-associated vasculature in the animal
model and of angiogenesis markers in the tumor lesions. We finally
found that changes in the expression levels were important,
particularly of genes known to be involved in the cell survival
pathway, p53 pathway, and NFAT pathway involved in modu-
lation of the immune response. This co-treatment of As4O6 and
PDT induced significantly enhanced antitumor effects, both in vitro
and in vivo, compared to those of each treatment alone. This seems
to indicate that the presence of As4O6 might increase the
antitumor effect of PDT by inducing changes in the expression
of genes involved in cell survival, p53, and NFAT pathways. In the
future, this co-treatment method of PDT and As4O6 may lead to
improved results of antitumor therapy.
Materials and Methods
Ethics Statement
All procedure of animal research were provided in accordance
with the Laboratory Animals Welfare Act, the Guide for the Care
and Use of Laboratory Animals and the Guidelines and Policies
for Rodent experiment provided by the IACUC (Institutional
Animal Care and Use Committee) in school of medicine, The
Catholic University of Korea [permit no: CUMC-2008-0061-02].
Cell cultures
TC-1 cells prepared by transformation of C57BL/6 primary
mouse lung cells with HPV16 E6/E7 oncogene and activated H-
RAS as have been kindly provided from the cell line bank at Johns
Hopkins University (a kind gift from Dr. Wu, Johns Hopkins
University, MD, USA). The cells were routinely propagated in
monolayer cultures in RPMI-1640 medium, supplemented with
5% heat-inactivated fetal bovine serum, 0.22% sodium bicarbon-
ate, and penicillin/streptomycin. The cells were cultured in a 5%
CO2 incubator at 37uC.
Photosensitizer and laser
The PDT was carried out using a diode laser generator
apparatus (Won-PDT D662, Won Technology, Daejon, Korea)
equipped with a halogen lamp, a band-pass filter and a fiber optics
bundle. The wavelength was set at 6626 2 nm. Under PDT
treatment, duration of the light irradiation was calculated taking
into account the effective dose of light energy in J/cm
2.
Radachlorin (RADA-PHARMA Co, Ltd., Moscow, Russia) was
used as a photosensitizer.
Arsenic compound
As4O6 was provided by Chonjisan Co. (Seoul, Korea). These
chemicals were diluted in phosphate-buffered saline (PBS) and
kept at 4uC.
MTT assay
To assess cell viability by PDT plus As4O6, TC-1 cells (3610
3)
were treated with 3 uM of As4O6 and/or 0.15 ug/ml, and 2.0 ug/
ml of Radachlorin (RADA-Parma). After incubation for 12 hrs,
the cells were washed with fresh medium and exposed to PDT
(6.25 J/cm
2). The cells were then further incubated at 37uC for 1,
2, 3, or 4 days, in a humidified incubator. After incubation with
Table 2. Gene expression profiles of TC-1 cells treated with
0.15 ug/ml Radachorin/PDT and/or 3 uM of As4O6 for 1 day.
Symbol As4O6 PDT
PDT +
As4O6 Symbol As4O6 PDT
PDT +
As4O6
Odc1 13064.2 21.1 9131.7 Icam1 1.4 5.0 1.9
Cebpb 6309.6 384.5 4319.6 Tmepai 5.4 8.6 1.8
Igfbp4 4683.4 7315.1 2413.1 Cdkn2b 1.4 2262.0 1.2
Egr1 1317.3 21.1 1495.8 Birc3 21.5 21.2 1.1
Fos 1513.1 5281.3 1043.1 Hk2 22.1 24.3 1.1
Jun 977.8 4927.6 1035.9 Bmp2 21.5 214.2 21.0
Bmp4 964.3 1000.6 414.9 Cdh1 4.3 21.1 21.2
Cdk2 254.8 22.4 371.4 Trp53 21.7 24.5 21.3
Hspb1 67.8 81.4 118.3 Bax 22.2 21.5 21.4
Ikbkb 68.8 279.5 106.6 Fn1 22.3 2.0 21.7
Wisp1 68.8 150.8 56.0 Ptch1 22.4 1.1 21.8
Mdm2 12.1 71.8 46.1 Hhip 5.3 1.7 22.0
Hoxa1 17.4 45.2 32.6 Tfrc 725.8 21.1 22.2
Brca1 8.0 24.2 31.3 Mmp7 4.8 21.1 22.2
Ccl2 108.6 21.1 27.8 Cxcl1 23.9 21.1 22.2
Aip 1 3.3 21.1 17.0 Birc5 21.4 2229.7 22.4
Bcl2 8.5 32.8 13.3 Lef1 22.2 21.7 22.5
p21 3.8 12.0 13.1 Tank 40.3 21.7 23.3
Mmp10 2.5 6.0 12.7 Fgf4 2.1 22.4 24.9
Vcam1 6.5 12.4 10.6 Cdkn2a 21.7 21.3 25.3
Nrip1 3.9 35.9 10.3 Sele 22.3 22.6 25.3
Ptgs2 2.6 9.8 9.5 Irf1 24.7 22.2 26.3
Igfbp3 6.8 44.8 8.0 Il1a 1.2 21.6 27.5
Cdkn1b 4.0 43.0 7.0 Nab2 24.2 22.1 27.9
Vegfa 3.7 276.3 5.6 Nos2 22.4 26.3 212.7
Bcl2l1 10.7 2170.5 5.6 Il2 1.0 22.6 217.2
En1 2.0 3.0 4.9 Rbp1 24.9 25.7 219.3
Gadd45a 2.5 5.2 4.7 Tert 22.7 217.2 234.6
Selp 5.1 21.5 4.4 Nfkbia 22.1 21055.2 22125.1
Myc 4.6 2174.0 3.9
Atf2 21.1 255.5 3.3
Fas 1.9 10.1 2.5
Ly-12
(Cd5)
1.9 3.3 2.3
Fasn 1.5 4.2 2.1
doi:10.1371/journal.pone.0038583.t002
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yl)-2,5-diphenyltetrazolium bromide (MTT) solution (2 mg/ml)
was added to each well and cultured for 4 h. One hundred
microliters of dimethyl sulfoxide (DMSO) was added to each well
for 10 min, and the absorbance was measured with an automated
spectrophotometric microtiter plate reader (SpectraMax 340;
Molecular Devices, Sunnyvale, CA), using a 570-nm filter. The
morphological changes of the cells were determined by optical
microscopy.
Evaluation of in vitro combination effects by the Chou-
Talalay method
The combined effects of Radachlorin/PDT and As4O6 on cell
survival were analyzed using Chou-Talalay method, which applies
the median-effect equation of Chou and the CI equation of Chou
and Talalay [34]. TC-1 cells were plated in 96-well microplates as
above were exposed in triplicate to each agent or both in
combination using the constant ratio combination design for
96 hours, followed by the MTT assay for cell viability de-
termination. Calculated CIs were used to ascertain the presence of
strong synergism (CI,0.3), moderate synergism (0.3, CI,0.9),
additive effect (CI=1), antagonism (CI.1) and strong antagonism
(CI.3.3) between Radachlorin/PDT and As4O6.
FACS analysis
TC-1 cells were washed twice with PBS and then resuspended
in 1X binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM
NaCl, 2.5 mM CaCl2). Then, 16105 cells per tube were added
with 5 ml of Annexin V-FITC and 10 ml of propidium iodide (BD,
San Jose, CA), followed by incubation at 22uC for 15 min. Each
tube was added with 100 m of 1X binding buffer and then the cells
were analyzed by a flow cytometer (BD). The samples were read
using flow cytometer (BD). Cell debris and fixation artifacts were
gated out using the CellQuest program.
Figure 5. In vivo effect of the combination of As4O6 and Radachlorin/PDT on tumor growth inhibition in TC-1 cell-challenged C57BL/
6 mice. (A) Tumor growth curves for TC-1 of mice treated with Radachlorin/PDT and/or As4O6 (n=7 for each group). Tumor bearing mice were given
intravenously injected Radachlorin (10 mg/kg b.w.) and/or peritoneal injections of 7.5 mg/kg of As4O6. Three hours later, cells were exposed to laser,
tumor size was monitored thereafter, as described in Materials and Methods, and its mean ellipsoid volume was plotted over time. Significant
inhibition of tumor growth was detected by ANOVA. *: P,0.01, compared with the control group, #: P,0.01, compared with the Radachlorin/PDT
alone group and $: P,0.01, compared with the As4O6 alone group. (B) Perfusion and morphological changes in TC-1 tumors in C57BL/6 mice treated
with As4O6 (10 mg/kg b.w., i.p.). Tumor tissues were harvested after 48 h after As4O6 treatment. Tissue were viewed at a wavelength of 365 nm and
photographed at x200 magnification. (C) Percent area of perfusion area of TC-1 tumors in C57BL/6 mice treated with As4O6 compared with non
treated tumors. The tumor tissues were harvested at indicated times after As4O6 treatment. Sequential changes of perfused areas at 1, 3, 6, 12, 24, and
48 hr after As4O6 treatment. *P,0.05, compared to untreated controls. (D) CD31-immunostained tumor sections (original magnification, x400) and
As4O6-treated sections are displayed. Twenty-four hours after As4O6 treatment, TC-1 tumors showed extensive loss of CD31 staining indicative of
significant As4O6-induced vascular damage.
doi:10.1371/journal.pone.0038583.g005
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TC-1 cells were treated with 3 uM of As4O6 and/or 0.15 ug/ml
of Radachlorin (RADA-Parma). After incubation for 12 hrs, the
cells were washed with fresh medium and exposed to light. The
following four groups were used in this study: control, 3 uM of
As4O6, 0.15 ug/ml of Radachlorin/irradiation, and 3 uM of
As4O6 plus 0.15 ug/ml of Radachlorin/irradiation. For all groups,
cells were harvested 24 h after irradiation. Total RNA was isolated
from cells according to the manufacturer’s recommendations using
TRIzol and the Absolutely RNA kit from Stratagene. RNA (2 mg)
was reverse transcribed in a total volume of 20 ml, using 200 U of
Superscript II (Invitrogen) reverse transcriptase, 100 pmol oligo-
dT, 0.5 mM dNTP, and 40 U RNasin (Promega). The resultant
cDNA was diluted 1:100 with nuclease-free water. Five microliters
of diluted cDNA was used in subsequent PCR reactions. Samples
for each group were analyzed according to the manufacturer’s
recommendations, using the ‘‘Mouse Signal Transduction
PathwayFinder (89 genes including 5 housekeeping genes)’’ array
in conjunction with the RT
2 Profiler PCR Array System from
SuperArray Bioscience (Frederick, MD). The results are presented
as transcript levels relative to the levels in untreated control cells
with average mRNA levels of five internal control genes, including
beta-actin, used as the normalization control. To verify changes in
gene expression, real-time PCR was carried out on 12 selected
genes. All primers were designed based on nucleotide sequences
retrieved from Genbank using the Primer Express software (PE
Applied Biosystems) (Supplementary Table S1).
Analyses
Genes that showed differences in their expression levels were, of
at least 2.0 fold, selected for the different analyses (hierarchical
cluster analysis, functional cluster analysis, biological pathway
analysis). Hierarchical clustering (GENE CLUSTER v3.0) and
display programs (TREE VIEW) were also used for analysis
(http://rana.stanford.edu/software). We performed unsupervised
hierarchical clustering based on the most variably expressed genes
using the Euclidean distance as the similarity metric and the
average linkage method as the between-cluster distance metric. A
t-test was also performed to find genes that have changed between
PDT alone and As4O6 alone, and PDT plus As4O6 treatment.
Supervised clustering of experimental samples was performed by
reducing the number of genes by statistical analysis. To classify the
gene expression profiles, functional analyses and KEGG (Kyoto
Encyclopedia for Genes and Genomes) pathway analyses (http://
www.genome.jp/kegg/pathway.html) were carried out as pre-
viously described [35,36]. To perform a KEGG analysis,
differentially expressed genes of each treatment group were used
for the calculation of their attribution to pre-defined KEGG
signaling pathways and analyzed by pair-wise comparisons. The
different number of genes were seen in a given pathway. The
Ingenuity Pathway Analysis software (IPA, Ingenuity Systems,
Mountain View, CA) was utilized to identify networks of
interacting genes and other functional groups. Semantically
consistent pathway relationships were modeled based on a contin-
ual, formal extraction from the public domain literature (www.
ingenuity.com/products/pathways_ knowledge.html).
Evaluation of in vivo antitumor effect
TC-1 cells (2610
5) were injected subcutaneously into the right
flank of C57BL/6 mice. Tumor-bearing mice were injected ip
with 7.5 mg/kg of As4O6 and/or intravenously injected with
Radachlorin (10 mg/kg). Three hours after injection, the animals
Figure 6. In vivo gene expression profiles in tumor tissues treated with 0.15 ug/ml Radachlorin/PDT or/and 3 uM of As4O6 for 1 day.
(A) The expression of genes mRNA in tumor tissues was examined by Q-PCR. The results are presented as transcript levels relative to the level in
untreated control cells by using the CT method, with b-actin mRNA levels used as the normalization control. (B) Western blot analysis of in vivo tumor
tissues treated with 0.15 ug/ml Radachlorin/PDT or/and 3 uM of As4O6 for several days.
doi:10.1371/journal.pone.0038583.g006
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cm
2 via a light fiber inserted into the tumor mass. Each group
included 7 animals. Tumor volume was determined in vivo by
external caliper using the pi-based ellipsoid volume formula
(length x depth x width x 0.5233) [37,38]. The average value and
standard deviation are based on calculated tumor volumes from
the eight mice in each group. To assess tumor response, tumor
growth was recorded every 2–3 days for 25 days. Tumor growth
was measured 2–3 times a week using calipers.
Western blot analysis
TC-1 cells were treated with 3 uM of As4O6 and/or 0.15 ug/ml
of Radachlorin. The cell lysates (approximately 30 mg of protein)
were separated in 12% polyacrylamide SDS-gels and transferred
to a nitrocellulose membrane (Schleicher & Schuell, Dassel,
Germany). This was then immersed in blocking buffer (5% skim
milk and 0.1% Tween 20 in PBS, pH 7.4) for 1 h at room
temperature and incubated with primary antibodies: (SantaCruz
Biotechnology, Inc., California, USA), p53 (1:200), GaDD45
(1:200), p21 (1:200), and actin (1:5000) in blocking buffer
overnight at 4uC. After incubation, the membrane was probed
with horseradish peroxidase-labeled anti-mouse IgG antibody
(1:5000) in PBS (containing of 0.05% Tween 20 and 5% skim milk
powder) for 30 min at room temperature. The proteins in the
membrane were detected by an enhanced chemiluminescence
detection system (Amersham, Buckinghamshire, UK) and the
bands were visualized by autoradiography using X-ray film
(Amersham).
Blood perfusion analysis after As4O6 treatment
Hoechst 33342 (Sigma-Aldrich) was dissolved in a sterile
phosphate-buffered saline (PBS) at a concentration of 3 mg/ml
and injected intravenously (i.v.) 0.10 ml/20 g mouse. TC-1
tumor-bearing mice (n=3) were divided into 1, 3, 6, 12, 24, 48,
72, 168 h post-As4O6 treatment groups. As the control, three mice
(i.p. injected PBS) used in each time point. One minute before
killing, mice were perfused with 15 mg/kg Hoechst 33342.
Tumors were excised and immediately frozen in liquid nitrogen.
Frozen tissues were embedded into OCT cryofixative (Sakura
Finetek, Janpan) and tumor cryo-sections were cut using
a CM1850UV cryostat microtome (Leica, Germany) and air-
dried. All the processes were performed quickly and samples were
protected from direct expose to light. Hoechst 33342 distribution
was assessed using a AX70, TR-62A02 fluorescent microscope
(Olympus, Tokyo, Japan). A scan consisted of a field-by field
movement of the scanning stage based on a selectable meander
pattern, depending on the tumor size. In each field, the
microscopic image was recorded and processed; during the image
processing using the Image Pro Plus digital image analysis system
(Media Cybernetics, USA). Each picture was converted into a gray
scale and the positive range value was fixed, and the percentage of
the positive area to the whole tumor area was determined.
Immunohistochemistry
Immunohistochemistry was used to analyze the expression of
CD31. Tumor tissues were fixed in 4% paraformaldehyde,
embedded in paraffin, and sectioned at 4 mm thickness. Tumor
sections were deparaffinized, rehydrated, and quenched with 3%
hydrogen peroxide for 10 min at room temperature. The sections
were incubated in protein blocking solution for 20 min before the
addition of the primary antibody. The sections were incubated for
2 h at 37uC with a 1:50 dilution of rabbit anti-mouse CD31
(Abcam, UK). After incubation, the sections were washed in PBS
for 5 min and anti-rabbit secondary biotinylated antibody was
applied. After washings, the avidin-biotin complex was then
applied to the sections, followed by extensive washing steps. A
diaminobenzidine chromogen kit (Abcam) was used to develop
sections.
Histopathology
Animals were treated with 10 mg/kg of As4O6. At selected time
points, tumors were excised and fixed in 4% neutral formalin and
embedded in paraffin. Paraffin-embedded tissues were sectioned
for routine staining with hematoxylin and eosin.
Real-time PCR microarray analysis with TC-1 tumor tissue
TC-1 cells (2610
5) were injected subcutaneously into the right
flank of C57BL/6 mice. Tumor-bearing mice were injected ip
with 7.5 mg/kg As4O6 and/or intravenously injected with
Radachlorin (10 mg/kg). Three hours after injection, the animals
were anaesthetized and the tumors were irradiated with 300 J/
cm
2 via a light fiber inserted into the tumor mass. One day after
treatment, animals were sacrificed and tumor tissue was harvested.
Total RNA was isolated from tumor tissue according to the
manufacturer’s recommendations, using TRIzol and the Abso-
lutely RNA kit from Stratagene. Real-time PCR was carried out
on 13 selected genes, as described previously.
Treatments interaction analysis
To determine the nature of the interaction between Rada-
chlorin/PDT and As4O6 treatment, the data from the MTT assay
were analyzed as reported previously [34] using CalcuSyn V2.0
software, (Biosoft, Cambridge, UK) [39]. The interaction of
treatments was quantified determining a combination index (CI).
CI , or .1 indicated synergy or antagonism respectively, whereas
a CI value of 1 indicates additivity [40].
Statistical analysis
Statistical analysis included ANOVA and the Student’s t-test.
The values for the different groups were compared. P values of less
than 0.05 were considered statistically significant.
Supporting Information
Figure S1 In vitro cell growth inhibitory effects of As4O6 and/
or Radachlorin/PDT on HaCaT, HeLa, and SiHa cells. Each cell
was cultured with 3 uM of As4O6 and/or 0.15 ug/ml of
Radachlorin/PDT, respectively. Cell viability was determined
based on the MTT assay. Each bar represents a mean [6 SD
(vertical line)] of three replicates (n=3).
(TIF)
Figure S2 Cell apoptosis analysis using Annexin V/PI staining.
TC-1 cells were cultured with 3 uM of As4O6 and/or 0.15 ug/ml
of Radachlorin/PDT for 1 day. Cell pellet was resuspended in
500 ml annexin V HEPES solution (10 mM HEPES-NaOH,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) and incubated on ice for
30 min in the dark. Cells were then washed once in ice-cold
HEPES buffer and PI was added just before FACS analysis. The
results were analyzed with a FACS.
(TIF)
Table S1 Primer sequences used for PCR assays.
(DOC)
Acknowledgments
We thank Ph.D student Pankaj Kumar Chaturvedi for analysis and
technical assistance.
Synergistic Combination of Photodynamic Therapy
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38583Author Contributions
Conceived and designed the experiments: YWK WSA. Performed the
experiments: SMB GB HJB. Analyzed the data: YWK WSA SMB.
Contributed reagents/materials/analysis tools: SMB HJB GB. Wrote the
paper: YWK WSA.
References
1. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, et al. (2005) Hyperbaric
oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor
surgery and phototherapy. Med Sci Monit 11: RA279–289.
2. Moserova I, Kralova J (2012) Role of ER Stress Response in Photodynamic
Therapy: ROS Generated in Different Subcellular Compartments Trigger
Diverse Cell Death Pathways. PLoS One 7: e32972.
3. Corti L, Mazzarotto R, Belfontali S, De Luca C, Baiocchi C, et al. (1996)
Photodynamic therapy in gynaecological neoplastic diseases. J Photochem
Photobiol B 36: 193–197.
4. Gomer CJ, Rucker N, Ferrario A, Wong S (1989) Properties and applications of
photodynamic therapy. Radiat Res 120: 1–18.
5. Wei Y, Kong B, Song K, Qu X, Jin Q, et al. (2007) Involvement of
mitochondria-caspase pathway in Hemoporfin-mediated cell death. Photochem
Photobiol 83: 1319–1324.
6. Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, et al. (2009)
Increased tumour dihydroceramide production after Photofrin-PDT alone and
improved tumour response after the combination with the ceramide analogue
LCL29. Evidence from mouse squamous cell carcinomas. Br J Cancer 100:
626–632.
7. Cheung WM, Chu PW, Kwong YL (2007) Effects of arsenic trioxide on the
cellular proliferation, apoptosis and differentiation of human neuroblastoma
cells. Cancer Lett 246: 122–128.
8. Woo SH, Park MJ, An S, Lee HC, Jin HO, et al. (2005) Diarsenic and
tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced
proliferation of human endothelial cells. J Cell Biochem 95: 120–130.
9. Yoo MH, Kim JT, Rhee CH, Park MJ, Bae IJ, et al. (2004) Reverse effects of
tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat
cornea. J Vet Med Sci 66: 1091–1095.
10. Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, et al. (2004) Comparison of
effects of As2O3 and As4O6 on cell growth inhibition and gene expression
profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12: 573–580.
11. Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC, et al. (2011) Role and
mechanism of arsenic in regulating angiogenesis. PLoS One 6: e20858.
12. Germolec DR, Yoshida T, Gaido K, Wilmer JL, Simeonova PP, et al. (1996)
Arsenic induces overexpression of growth factors in human keratinocytes.
Toxicol Appl Pharmacol 141: 308–318.
13. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al. (1996) In vitro studies on
cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment
of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with
downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML
proteins. Blood 88: 1052–1061.
14. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, et al. (1998) Arsenic
trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute
promyelocytic leukemia cells. J Natl Cancer Inst 90: 124–133.
15. Banerjee N, Banerjee M, Ganguly S, Bandyopadhyay S, Das JK, et al. (2008)
Arsenic-induced mitochondrial instability leading to programmed cell death in
the exposed individuals. Toxicology 246: 101–111.
16. Laparra JM, Velez D, Barbera R, Farre R, Montoro R (2008) As2O3-induced
oxidative stress and cycle progression in a human intestinal epithelial cell line
(Caco-2). Toxicol In Vitro 22: 444–449.
17. Rigas B, Sun Y (2008) Induction of oxidative stress as a mechanism of action of
chemopreventive agents against cancer. Br J Cancer 98: 1157–1160.
18. Rigas B (2007) The use of nitric oxide-donating nonsteroidal anti-inflammatory
drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol
23: 55–59.
19. Gao J, Liu X, Rigas B (2005) Nitric oxide-donating aspirin induces apoptosis in
human colon cancer cells through induction of oxidative stress. Proc Natl Acad
Sci U S A 102: 17207–17212.
20. Sun Y, Rigas B (2008) The thioredoxin system mediates redox-induced cell
death in human colon cancer cells: implications for the mechanism of action of
anticancer agents. Cancer Res 68: 8269–8277.
21. Buytaert E, Dewaele M, Agostinis P (2007) Molecular effectors of multiple cell
death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776:
86–107.
22. Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M (2001) The correlation of
TERT expression with c-myc expression in cervical cancer. Cancer Lett 168:
45–50.
23. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-
tumour immunity. Nat Rev Cancer 6: 535–545.
24. Kammerer R, Buchner A, Palluch P, Pongratz T, Oboukhovskij K, et al. (2011)
Induction of immune mediators in glioma and prostate cancer cells by non-lethal
photodynamic therapy. PLoS One 6: e21834.
25. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T (2006) Mechanistic
investigation and implications of photodynamic therapy induction of vascular
endothelial growth factor in prostate cancer. Cancer Res 66: 5633–5640.
26. Nakagawa H, Matsumiya T, Sakaki H, Imaizumi T, Kubota K, et al. (2007)
Expression of vascular endothelial growth factor by photodynamic therapy with
mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma. Oral Oncol
43: 544–550.
27. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, et al. (2000)
Antiangiogenic treatment enhances photodynamic therapy responsiveness in
a mouse mammary carcinoma. Cancer Res 60: 4066–4069.
28. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ (2002) Cyclooxygenase-2
inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Cancer Res 62: 3956–3961.
29. Ferrario A, Fisher AM, Rucker N, Gomer CJ (2005) Celecoxib and NS-398
enhance photodynamic therapy by increasing in vitro apoptosis and decreasing
in vivo inflammatory and angiogenic factors. Cancer Res 65: 9473–9478.
30. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, et al. (2004) The
matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy
responsiveness in a mouse tumor model. Cancer Res 64: 2328–2332.
31. Gomer CJ, Ferrario A, Luna M, Rucker N, Wong S (2006) Photodynamic
therapy: combined modality approaches targeting the tumor microenvironment.
Lasers Surg Med 38: 516–521.
32. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide
causes selective necrosis in solid murine tumors by vascular shutdown. Cancer
Res 59: 6033–6037.
33. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, et al. (1999)
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects
in tumors and normal tissues. Cancer Res 59: 1626–1634.
34. Chou TC (2010) Drug combination studies and their synergy quantification
using the Chou-Talalay method. Cancer Res 70: 440–446.
35. Pletcher SD, Macdonald SJ, Marguerie R, Certa U, Stearns SC, et al. (2002)
Genome-wide transcript profiles in aging and calorically restricted Drosophila
melanogaster. Curr Biol 12: 712–723.
36. Wang JL, Lin YW, Chen HM, Kong X, Xiong H, et al. (2011) Calcium prevents
tumorigenesis in a mouse model of colorectal cancer. PLoS One 6: e22566.
37. Goodwin SC, Bonilla SC, Sacks D, Reed RA, Spies JB, et al. (2003) Reporting
standards for uterine artery embolization for the treatment of uterine
leiomyomata. J Vasc Interv Radiol 14: S467–476.
38. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size
in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148–154.
39. Chou TC (2006) Theoretical basis, experimental design, and computerized
simulation of synergism and antagonism in drug combination studies. Pharmacol
Rev 58: 621–681.
40. Reynolds CP, Maurer BJ (2005) Evaluating response to antineoplastic drug
combinations in tissue culture models. Methods Mol Med 110: 173–183.
Synergistic Combination of Photodynamic Therapy
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38583